Back to Search Start Over

Preventable Complications Driving Rising Costs in Management of Patients with Critical Limb Ischemia.

Authors :
Dua A
Desai SS
Patel B
Seabrook GR
Brown KR
Lewis B
Rossi PJ
Malinowski M
Lee CJ
Source :
Annals of vascular surgery [Ann Vasc Surg] 2016 May; Vol. 33, pp. 144-8. Date of Electronic Publication: 2016 Feb 23.
Publication Year :
2016

Abstract

Background: This study aimed to identify factors that drive increasing health-care costs associated with the management of critical limb ischemia in elective inpatients.<br />Methods: Patients with a primary diagnosis code of critical limb ischemia (CLI) were identified from the 2001-2011 Nationwide Inpatient Sample. Demographics, CLI management, comorbidities, complications (bleeding, surgical site infection [SSI]), length of stay, and median in-hospital costs were reviewed. Statistical analysis was completed using Students' t-test and Mann-Kendall trend analysis. Costs are reported in 2011 US dollars corrected using the consumer price index.<br />Results: From 2001 to 2011, there were a total of 451,823 patients who underwent open elective revascularization as inpatients for CLI. Costs to treat CLI increased by 63% ($12,560 in 2001 to $20,517 in 2011, P < 0.001 in trend analysis). Endovascular interventions were 20% more expensive compared with open surgery ($19,566 vs. $16,337, P < 0.001). Age, gender, and insurance status did not affect the cost of care. From 2001 to 2011, the number of patient comorbidities (7.56-12.40) and percentage of endovascular cases (13.4% to 27.4%) increased, accounting for a 6% annual increase in total cost despite decreased median length of stay (6 to 5 days). Patients who developed SSI had total costs 83% greater than patients without SSIs ($30,949 vs. $16,939; P < 0.001). Patients who developed bleeding complications had total costs 41% greater than nonbleeding patients ($23,779 vs. $16,821, P < 0.001). Overall, there was a 32% reduction in SSI rates but unchanged rates of bleeding complications during this period.<br />Conclusions: The cost of CLI treatment is increasing and driven by rising endovascular use, SSI, and bleeding in the in-patient population. Further efforts to reduce complications in this patient population may contribute to a reduction in health care-associated costs of treating CLI.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1615-5947
Volume :
33
Database :
MEDLINE
Journal :
Annals of vascular surgery
Publication Type :
Academic Journal
Accession number :
26916348
Full Text :
https://doi.org/10.1016/j.avsg.2015.11.026